PLAT and stroke disorder: Even though this trial found promising results and was a randomized, blinded, safety trial measuring low-dose r-tPA plus eptifibatide, it had a marked disparity in age and baseline NIH Stroke Scale/Score (NIHSS) between the combination therapy and the control groups [3].